Macrocycles in new drug discovery

Future Medicinal Chemistry

Volumn 4, Issue 11, 2012, Pages 1409-1438

  Mallinson, Jamie ^a   Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE INHIBITOR; CD135 ANTIGEN; CILENGITIDE; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOSPORIN A; EPOTHILONE B; HEAT SHOCK PROTEIN 90 INHIBITOR; IXABEPILONE; JANUS KINASE 2 INHIBITOR; MACROCYCLIC COMPOUND; MOLECULAR SCAFFOLD; PACRITINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADICICOL; REBECCAMYCIN; RENIN INHIBITOR; RUBOXISTAURIN; STAUROSPORINE; TANESPIMYCIN; TEMSIROLIMUS; ZEARALENONE;

CANCER GROWTH; COMPUTER MODEL; CRYSTAL STRUCTURE; CYCLIZATION; DRUG CONFORMATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENTHALPY; ENTROPY; ENZYME INHIBITION; EPOXIDATION; HUMAN; HYDROGEN BOND; HYDROGENATION; IC 50; LIVER MICROSOME; MOLECULAR DOCKING; MOLECULAR STABILITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; REVIEW; RING CLOSING METATHESIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BINDING SITES; BIOLOGICAL AGENTS; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HUMANS; MACROCYCLIC COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864679725     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.93     Document Type: Review

References (99)

1. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat. Rev. Drug Discov. 7(7), 608-624 (2008). (Pubitemid 351927725)
2. Oyelere AK. Macrocycles in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 10(14), 1359-1360 (2010).
3. Marsault E, Peterson ML. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 54(7), 1961-2004 (2011).
4. Avolio S, Summa V. Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease. Curr. Top. Med. Chem. 10(14), 1403-1422 (2010).
5. Brandt W, Haupt VJ, Wessjohann LA. Chemoinformatic analysis of biologically active macrocycles. Curr. Top. Med. Chem. 10(14), 1361-1379 (2010).
6. Giamarellos-Bourboulis EJ. Macrocycle molecules for the management of systemic infections: the clarithromycin paradigm. Curr. Top. Med. Chem. 10(14), 1470-1475 (2010).
7. Johnson VA, Singh EK, Nazarova LA, Alexander LD, Mcalpine SR. Macrocyclic inhibitors of hsp90. Curr. Top. Med. Chem. 10(14), 1380-1402 (2010).
8. Mwakwari SC, Patil V, Guerrant W, Oyelere AK. Macrocyclic histone deacetylase inhibitors. Curr. Top. Med. Chem. 10(14), 1423-1440 (2010).
9. Ying L, Tang D. Recent advances in the medicinal chemistry of novel erythromycinderivatized antibiotics. Curr. Top. Med. Chem. 10(14), 1441-1469 (2010).
10. Smith B, March J. March's Advanced Organic Chemistry: Reactions, Mechanisms and Structure (5th Edition). Wiley, New York, NY, USA, 184-186 (2001).
11. Wessjohann LA, Ruijter E, Garcia-Rivera D, Brandt W. What can a chemist learn from nature's macrocycles? A brief, conceptual view. Mol. Divers. 9(1), 171-186 (2005). (Pubitemid 40394851)
12. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15(4), 428-435 (2010).
13. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22(12), 2336-2347 (2004). (Pubitemid 41115390)
14. Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P. Ixabepilone. Nat. Rev. Drug Discov. 6(12), 953-954 (2007). (Pubitemid 350201785)
15. Goodin S. Novel cytotoxic agents: epothilones. Am. J. Health Syst. Pharm. 65(10, Suppl. 3), S10-S15 (2008).
16. Goodin S. Ixabepilone: a novel microtubulestabilizing agent for the treatment of metastatic breast cancer. Am. J. Health Syst. Pharm. 65(21), 2017-2026 (2008).
17. Mcdonald E, Workman P, Jones K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 6(11), 1091-1107 (2006). (Pubitemid 44110922)
18. Hart S, Goh KC, Novotny-Diermayr V et al. SB1518, a novel macrocyclic pyrimidinebased JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25(11), 1751-1759 (2011).
19. Komrojki RS, Wadleigh M, Seymour JF et al. Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego Convention Center, San Diego, CA, USA, 10-13 December 2011.
20. William AD, Lee ACH, Goh KC et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20- oxa5,7,14,26-tetraazatetracyc lo19.3.1.1(2,6).1(8,12)heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J. Med. Chem. 55(1), 169-196 (2012).
21. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate. design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10(10), 753-768 (2010).
22. Stupp R, Van Den Bent MJ, Erridge SC et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). J. Clin. Oncol. 28(15s), TPS152 (2010).
23. Hirai H, Takahashi-Suziki I, Shimomura T et al. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest. New Drugs 29(4), 534-543 (2011).
24. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001). (Pubitemid 33653411)
25. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat. Chem Biol. 2(12), 689-700 (2006). (Pubitemid 44764211)
26. Lipinski CA. Compound properties and drug quality. In: In The Practice of Medicinal Chemistry (Second Edition). Wermuth C (Ed.). Academic Press, London, UK, 341 (2003).
27. Vieth M, Siegel MG, Higgs RE et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47(1), 224-232 (2004). (Pubitemid 38040506)
28. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615-2623 (2002). (Pubitemid 34595232)
29. Lu JJ, Crimin K, Goodwin JT et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J. Med. Chem. 47(24), 6104-6107 (2004). (Pubitemid 39507351)
30. Harvey AL. Natural products in drug discovery. Drug Discov. Today 13(19-20), 894-901 (2008).
31. Mann A. Conformational restriction and/or steric hindrance in medicinal chemistry. In: The Practice Of Medicinal Chemistry, Wermuth CG (Ed.). Academic Press, London, UK (2008).
32. Reynolds CH, Holloway MK. Thermodynamics of ligand binding and efficiency. ACS Med. Chem. Lett. 2(6), 433-437 (2011).
33. Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J. Med. Chem. 53(14), 5061-5084 (2010).
34. Sarkar A, Kellogg GE. Hydrophobicity - shake flasks, protein folding and drug discovery. Curr. Top Med. Chem. 10(1), 67-83 (2010).
35. Williams DH, Calderone CT, O'Brien DP, Zerella R. Changes in motion vs. bonding in positively vs. negatively cooperative interactions. Chem. Comm. (12), 1266-1267 (2002). (Pubitemid 34594554)
36. DeLorbe JE, Clements JH, Whiddon BB, Martin SF. Thermodynamic and structural effects of macrocyclic constraints in protein-ligand interactions. ACS Med. Chem. Lett. 1(8), 448-452 (2010).
37. Tao Z-F, Wang L, Stewart KD et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J. Med. Chem. 50(7), 1514-1527 (2007). (Pubitemid 46564373)
38. Proisy N, Sharp SY, Boxall K et al. Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. Chem. Biol. 13(11), 1203-1215 (2006). (Pubitemid 44750734)
39. Lücking U, Siemeister G, Schäfer M et al. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities. ChemMedChem 2(1), 63-77 (2007).
40. Nie Z, Perretta C, Erickson P et al. Structurebased design and synthesis of novel macrocyclic pyrazolo1,5-a1,3,5triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg. Med. Chem. Lett. 18(2), 619-623 (2008).
41. Ishikawa M, Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J. Med. Chem. 54(6), 1539-1554 (2011).
42. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52(21), 6752-6756 (2009).
43. Huang Y, Strobel ED, Ho CY et al. Macrocyclic BACE inhibitors: optimization of a micromolar hit to nanomolar leads. Bioorg. Med. Chem. Lett. 20(10), 3158-3160 (2010).
44. Baxter EW, Conway KA, Kennis L et al. 2-amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β-site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead. J. Med. Chem. 50(18), 4261-4264 (2007). (Pubitemid 47378825)
45. Stachel SJ, Coburn CA, Sankaranarayanan S et al. Macrocyclic inhibitors of β-secretase: functional activity in an animal model. J. Med. Chem. 49(21), 6147-6150 (2006). (Pubitemid 44595189)
46. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9(10), 430-431 (2004). (Pubitemid 38510559)
47. Zhang H-C, Boñaga LVR, Ye H, Derian CK, Damiano BP, Maryanoff BE. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 17(10), 2863-2868 (2007). (Pubitemid 46636245)
48. Bartlett S, Beddard GS, Jackson RM et al. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. J. Am. Chem. Soc. 127(33), 11699-11708 (2005). (Pubitemid 41208755)
49. Dakas P-Y, Barluenga S, Totzke F, Zirrgiebel U, Winssinger N. Modular synthesis of radicicol a and related resorcylic acid lactones, potent kinase inhibitors. Angew. Chem. Int. Ed. Engl. 46(36), 6899-6902 (2007). (Pubitemid 47425814)
50. Jogireddy R, Dakas P-Y, Valot G, Barluenga S, Winssinger N. Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases. Chem. Eur. J. 15(43), 11498-11506 (2009).
51. Moulin E, Barluenga S, Winssinger N. Concise synthesis of pochonin A, an HSP90 inhibitor. Org. Lett. 7(25), 5637-5639 (2005). (Pubitemid 43010817)
52. Moulin E, Barluenga S, Totzke F, Winssinger N. Diversity-oriented synthesis of pochonins and biological evaluation against a panel of kinases. Chem. Eur. J. 12(34), 8819-8834 (2006). (Pubitemid 44852467)
53. Sund C, Belda O, Wiktelius D et al. Design and synthesis of potent macrocyclic renin inhibitors. Bioorg. Med. Chem. Lett. 21(1), 358-362 (2011).
54. Linde Y, Ovadia O, Safrai E et al. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Peptide Sci. 90(5), 671-682 (2008).
55. Horswill AR, Benkovic SJ. Cyclic peptides, a chemical genetics tool for biologists. Cell Cycle 4(4), 552-555 (2005). (Pubitemid 41359779)
56. Mesaros EF, Burke JP, Parrish JD et al. Novel 2,3,4,5-tetrahydro- benzodazepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorg. Med. Chem. Lett. 21(1), 463-466 (2011).
57. Breslin HJ, Lane BM, Ott GR et al. Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo14.3.1.13,7.19,13 docosa-1(20),3(22),4,6,9(21),10,12, 16,18- nonaene macrocycles. J. Med. Chem. 55(1), 449-464 (2011).
58. Zapf CW, Bloom JD, Li Z et al. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model. Bioorg. Med. Chem. Lett. 21(15), 4602-4607 (2011).
59. Zapf CW, Bloom JD, Mcbean JL et al. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model. Bioorg. Med. Chem. Lett. 21(12), 3627-3631 (2011).
60. Zapf CW, Bloom JD, Mcbean JL et al. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity. Bioorg. Med. Chem. Lett. 21(8), 2278-2282 (2011).
61. Zapf CW, Bloom JD, Mcbean JL et al. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity. Bioorg. Med. Chem. Lett. 21(11), 3411-3416 (2011).
62. Huang KH, Veal JM, Fadden RP et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 52(14), 4288-4305 (2009).
63. Cho YS, Whitehead L, Li J et al. Conformational refinement of hydroxamatebased histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). J. Med. Chem. 53(7), 2952-2963 (2010).
64. Collins I, Rowley M, Davey WB et al. 3-(1-piperazinyl)-4,5-dihydro-1H- benzog indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels. Bioorg. Med. Chem. 6(6), 743-753 (1998). (Pubitemid 28287276)
65. Kawanishi N, Sugimoto T, Shibata J et al. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg. Med. Chem. Lett. 16(19), 5122-5126 (2006). (Pubitemid 44247696)
66. William AD, Lee ACH, Blanchard SP et al. Discovery of the macrocycle 11-(2-pyrrolidin- 1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracy clo19.3.1.1(2,6).1(8,12)heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J. Med. Chem. 54(13), 4638-4658 (2011).
67. Rezai T, Bock JE, Zhou MV, Kalyanaraman C, Lokey RS, Jacobson MP. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128(43), 14073-14080 (2006). (Pubitemid 44657500)
68. Rezai T, Yu B, Millhauser GL, Jacobson MP, Lokey RS. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. J. Am. Chem. Soc. 128(8), 2510-2511 (2006). (Pubitemid 43327908)
69. Augustijns PF, Brown SC, Willard DH et al. Hydration changes implicated in the remarkable temperature-dependent membrane permeation of cyclosporin A. Biochemistry 39(25), 7621-7630 (2000). (Pubitemid 30422082)
70. Kessler H, Köck M, Wein T, Gehrke M. Reinvestigation of the conformation of cyclosporin A in chloroform. Helv. Chim. Acta 73(7), 1818-1832 (1990). (Pubitemid 20353191)
71. Ko SY, Dalvit C. Conformation of cyclosporin A in polar solvents. Int. J. Pept. Protein Res. 40(5), 380-382 (1992).
72. Terrett NK. Methods for the synthesis of macrocycle libraries for drug discovery. Drug Discov. Today: Technologies 7(2), e97-e104 (2010).
73. Bogdan AR, Davies NL, James K. Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range. Org. Biomol. Chem. 9(22), 7727-7733 (2011).
74. Day JEH, Sharp SY, Rowlands MG et al. Targeting the Hsp90 molecular chaperone with novel macrolactams. synthesis, structural, binding, and cellular studies. ACS Chem. Biol. 6(12), 1339-1347 (2011).
75. Hunt JT. Discovery of ixabepilone. Mol. Cancer Ther. 8(2), 275-281 (2009).
76. Wessjohann LA, Ruijter E. Strategies for total and diversity-oriented synthesis of natural product(-like) macrocycles. In: Natural Product Synthesis I. Mulzer J (Ed.). Springer, Heidelberg, Berlin, Germany, 137-184 (2005). (Pubitemid 44423480)
77. Lee CW, Grubbs RH. Formation of macrocycles via ring-closing olefin metathesis. J. Org. Chem. 66(21), 7155-7158 (2001). (Pubitemid 32983107)
78. Tao Z-F, Sowin TJ, Lin N-H. Synthesis of macrocyclic urea kinase inhibitors. Synlett 18, 2855-2858 (2007). (Pubitemid 350189836)
79. Dandapani S, Marcaurelle LA. Grand challenge commentary: accessing new chemical space for 'undruggable' targets. Nat. Chem. Biol. 6(12), 861-863 (2010).
80. Yu M, Wang C, Kyle AF et al. Synthesis of macrocyclic natural products by catalystcontrolled stereoselective ring-closing metathesis. Nature 479(7371), 88-93 (2011).
81. Kim MJ, Lee SH, Park SO et al. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents. Bioorg. Med. Chem. 19(18), 5468-5479 (2011).
82. Winssinger N, Barluenga S. Chemistry and biology of resorcylic acid lactones. Chem. Commun. (1), 22-36 (2007). (Pubitemid 44913078)
83. Dakas P-Y, Jogireddy R, Valot G, Barluenga S, Winssinger N. Divergent syntheses of resorcylic acid lactones: L-783277, LL-Z1640- 2, and hypothemycin. Chem. Eur. J. 15(43), 11490-11497 (2009).
84. Balraju V, Iqbal J. Synthesis of cyclic peptides constrained with biarylamine linkers using Buchwald-Hartwig C-N coupling. J. Org. Chem. 71(23), 8954-8956 (2006). (Pubitemid 44721971)
85. Bogdan AR, James K. Synthesis of 5-iodo- 1,2,3-triazole-containing macrocycles using copper flow reactor technology. Organic Letters 13(15), 4060-4063 (2011).
86. Chouhan G, James K. CuAAC macrocyclization: high intramolecular selectivity through the use of copper-tris(triazole) ligand complexes. Org. Lett. 13(10), 2754-2757 (2011).
87. Malet Sanz L, Susanne F. Continuous flow synthesis. a pharma perspective. J. Med. Chem. 55(9), 4062-4098 (2012).
88. White CJ, Yudin AK. Contemporary strategies for peptide macrocyclization. Nat. Chem. 3(7), 509-524 (2011).
89. Tse BN, Snyder TM, Shen Y, Liu DR. Translation of DNA into a library of 13,000 synthetic small-molecule macrocycles suitable for in vitro selection. J. Am. Chem. Soc. 130(46), 15611-15626 (2008).
90. Hoveyda HR, Marsault E, Gagnon R et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (part I): development of ulimorelin (TZP-101) from hit to clinic. J. Med. Chem. 54(24), 8305-8320 (2011).
91. Rudd MT, Mccauley JA, Butcher JW et al. Discovery of MK-1220: a macrocyclic inhibitor of hepatitis C virus NS3/4A Protease with improved preclinical plasma exposure. ACS Med. Chem. Lett. 2(3), 207-212 (2011).
92. Hann MM. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2(5), 349-355 (2011).
93. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5(8), 671-688 (2006). (Pubitemid 44151605)
94. Choi J, Chen J, Schreiber SL, Jon C. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242 (1996). (Pubitemid 26285890)
95. Heinz DW, Schubert W-D, Höfle G. Much anticipated - the bioactive conformation of epothilone and its binding to tubulin. Angew. Chem. Int. Ed. Engl. 44(9), 1298-1301 (2005). (Pubitemid 40352555)
96. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 305(5685), 866-869 (2004). (Pubitemid 39038421)
97. Hung AW, Ramek A, Wang Y et al. Route to three-dimensional fragments using diversityoriented synthesis. Proc. Natl Acad. Sci. USA 108(17), 6799-6804 (2011).
98. Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design? Drug Discov. Today 14(21-22), 1011-1020 (2009).
99. Banerji U, O'Donnell A, Scurr M et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23(18), 4152-4161 (2005). (Pubitemid 46211321)